MDxHealth SA (NASDAQ:MDXH) Short Interest Up 53.2% in July

Key Points

• MDxHealth SA experienced a significant increase in short interest of 53.2% in July, with total short interest reaching 119,000 shares as of July 31.
• Institutional investors have been active, with notable transactions including a 459.1% increase in holdings by Delta Investment Management and a new stake of $273,000 from FreeGulliver LLC.
• The company's latest earnings report revealed an EPS of ($0.15), missing expectations, while setting a Q2 2025 EPS guidance of ($0.150) to ($0.150).

MDxHealth SA (NASDAQ:MDXH - Get Free Report) was the target of a significant increase in short interest in July. As of July 31st, there was short interest totaling 119,000 shares, anincreaseof53.2% from the July 15th total of 77,700 shares. Currently,0.3% of the company's stock are sold short. Based on an average daily volume of 80,200 shares, the short-interest ratio is currently 1.5 days. Based on an average daily volume of 80,200 shares, the short-interest ratio is currently 1.5 days. Currently,0.3% of the company's stock are sold short.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on MDXH. Craig Hallum started coverage on MDxHealth in a research report on Thursday, July 17th. They set a "buy" rating and a $8.00 price target on the stock. Wall Street Zen raised MDxHealth to a "hold" rating in a research report on Saturday, May 24th. Three analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, MDxHealth has a consensus rating of "Buy" and a consensus target price of $7.00.

MDxHealth Stock Performance

MDXH traded up $0.22 during midday trading on Friday, hitting $3.29. 234,618 shares of the company were exchanged, compared to its average volume of 134,264. The company's 50 day simple moving average is $2.42 and its 200 day simple moving average is $1.99. The firm has a market capitalization of $155.58 million, a price-to-earnings ratio of -3.74 and a beta of 1.41. The company has a current ratio of 1.31, a quick ratio of 1.22 and a debt-to-equity ratio of 13.81. MDxHealth has a 1-year low of $1.35 and a 1-year high of $3.29.

MDxHealth (NASDAQ:MDXH - Get Free Report) last posted its earnings results on Tuesday, August 5th. The company reported ($0.15) EPS for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.02). MDxHealth had a negative net margin of 34.98% and a negative return on equity of 374.98%. The business had revenue of $26.60 million for the quarter, compared to analyst estimates of $26.60 million. MDxHealth has set its Q2 2025 guidance at -0.150--0.150 EPS. As a group, sell-side analysts predict that MDxHealth will post -1.15 earnings per share for the current year.

Institutional Investors Weigh In On MDxHealth

A number of institutional investors have recently modified their holdings of MDXH. Geode Capital Management LLC acquired a new stake in shares of MDxHealth during the 4th quarter valued at about $25,000. Renaissance Technologies LLC grew its position in shares of MDxHealth by 715.2% during the 4th quarter. Renaissance Technologies LLC now owns 123,100 shares of the company's stock valued at $292,000 after acquiring an additional 108,000 shares during the period. XTX Topco Ltd acquired a new stake in shares of MDxHealth during the 4th quarter valued at about $63,000. Northern Right Capital Management L.P. acquired a new stake in shares of MDxHealth during the 4th quarter valued at about $246,000. Finally, Northern Trust Corp acquired a new stake in shares of MDxHealth during the 4th quarter valued at about $1,033,000.

MDxHealth Company Profile

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.